Does Mesenchymal Stem Cell Therapy Help Multiple Sclerosis Patients? Report of a Pilot Study

Area of Science:

• Neuroscience
• Immunology
• Regenerative Medicine

Background:

• Mesenchymal stem cells (MSCs) possess immunomodulatory properties and differentiation potential.
• These characteristics position MSCs as promising candidates for cell and gene therapy applications.

Purpose of the Study:

• To assess the therapeutic efficacy of autologous MSCs in ameliorating clinical symptoms of multiple sclerosis (MS) patients.
• To evaluate the safety and feasibility of intrathecal MSC transplantation in MS.

Main Methods:

• A pilot study involving ten MS patients with progressive disease unresponsive to standard treatments.
• Patients received intrathecal injections of culture-expanded autologous MSCs.
• Neurological assessments and MRI scans were conducted for follow-up.

Main Results:

• Over a mean follow-up of 19 months, one patient showed significant EDSS improvement, while five experienced worsening.
• Functional assessments revealed improvements in sensory, pyramidal, and cerebellar functions in six patients.
• MRI scans indicated no change in lesion load for seven patients, with two showing new plaques and one a decrease.

Conclusions:

• Autologous MSC transplantation is feasible for MS patients.
• Further investigation with larger patient cohorts is necessary to confirm therapeutic benefits and draw definitive conclusions.